Does bovine growth hormone in milk affect human growth hormone levels?

No. BGH does not raise human growth hormone or IGF-1 levels when consumed orally because it binds human somatotropin receptors with approximately 1000-fold lower affinity than endogenous human GH and is fully hydrolyzed by gastric pepsin and pancreatic proteases before reaching systemic circulation. Rat bioavailability studies confirm no detectable serum BGH or IGF-1 elevation following oral BGH administration.

Is bovine growth hormone in dairy products safe to consume?

Yes, BGH present in dairy is considered safe for human consumption by the FDA, WHO, and EFSA, based on its complete inactivation during digestion and its inability to bind human growth hormone receptors with meaningful affinity. Pasteurization also reduces BGH concentrations by approximately 19–90% depending on temperature and duration, further minimizing any theoretical exposure.

What is the difference between BGH and recombinant bovine somatotropin (rbST)?

Natural BGH is the endogenous 191-amino-acid polypeptide secreted by bovine pituitary tissue, while recombinant bovine somatotropin (rbST, brand name Posilac) is a synthetically produced version manufactured via recombinant DNA technology in E. coli that differs by one amino acid at the N-terminus. Both are biologically equivalent in cattle and equally inactive in humans via the oral route; rbST is a veterinary-approved injectable used to increase milk yield in dairy cows by 10–15%.

Can bovine growth hormone cause early puberty in children who drink milk?

Current scientific consensus does not support a causal link between BGH in milk and early puberty in children, as intact BGH cannot survive digestion or activate human receptors. Any observed associations between dairy consumption and growth markers in children are attributed to dairy's high content of protein, calcium, and bioavailable IGF-1 of human-analogous origin, not to BGH itself.

Why is bovine growth hormone species-specific and inactive in humans?

BGH's species-specificity arises from structural differences in the receptor-binding domains of bovine versus human somatotropin receptors (hGHR); the binding site 1 and site 2 helical epitopes on BGH do not geometrically complement the human GHR extracellular domain with sufficient affinity to trigger JAK2-STAT5 signal transduction. Human GH, by contrast, binds hGHR with a dissociation constant (Kd) in the low nanomolar range, while BGH's affinity is estimated to be three orders of magnitude weaker, producing no measurable receptor dimerization or downstream IGF-1 transcription in human hepatocytes.

What foods contain bovine growth hormone and how much BGH is naturally present?

Bovine growth hormone is naturally produced in cattle and present in conventional dairy products including milk, cheese, and yogurt at trace levels. The concentration of BGH in milk is typically less than 1 ng/mL in naturally-produced milk, and even lower in pasteurized products due to heat degradation. BGH levels are higher in dairy from cows treated with recombinant bovine somatotropin (rbST), though the hormone itself is still biologically inactive in human consumers due to species-specific receptor binding and complete digestive degradation.

Why is bovine growth hormone ineffective as a human supplement despite being promoted in some products?

BGH cannot function as a human supplement because it is a species-specific hormone with extremely low affinity for human somatotropin receptors, making it biologically inactive in humans even if absorbed. Additionally, BGH is completely degraded by digestive enzymes (proteases and peptidases) during normal digestion, preventing any systemic absorption or biological effects. Any marketed BGH supplement would provide no physiological benefit compared to placebo, as demonstrated in mechanistic and animal studies.

Should consumers specifically avoid BGH or rbST-treated dairy products for health reasons?

Regulatory agencies including the FDA have determined that BGH and rbST-treated dairy products are safe for human consumption, as BGH has no biological activity in humans and is degraded by digestion. Individual choice regarding BGH-containing products is typically based on personal preference, environmental concerns, or animal welfare considerations rather than direct human health risks. Consumers concerned about BGH exposure can choose organic or rBST-free labeled dairy products, which legally cannot come from rbST-treated cows, though the BGH hormone itself poses no demonstrated human health risk.

Bovine Growth Hormone (BGH) (Bos taurus)

Bovine Growth Hormone (BGH), also called bovine somatotropin (bST), is a 191-amino-acid polypeptide hormone produced by the anterior pituitary gland of cattle that regulates milk production and growth in bovines. It binds with very low affinity to human growth hormone receptors and is completely inactivated by gastrointestinal proteases, rendering it biologically inert in humans upon ingestion.

Category: Protein Evidence: 2/10 Tier: Emerging

Bovine Growth Hormone (BGH) (Bos taurus) — Hermetica Encyclopedia

Origin & History

Bovine Growth Hormone (BGH), also known as bovine somatotropin (bST), is a peptide hormone naturally produced by the pituitary glands of cows (Bos taurus) consisting of 190-191 amino acids. Commercial recombinant versions (rbST/rBGH) are produced via recombinant DNA technology in E. coli bacteria and administered as injectable formulations to dairy cattle for milk production enhancement.

Historical & Cultural Context

BGH has no historical context in traditional medicine systems as it is a naturally occurring bovine pituitary hormone not used traditionally in human medicine. Commercial rbST development began in the 1970s-1980s through biotechnology specifically for veterinary milk production enhancement, not for human therapeutic purposes.

Health Benefits

• No demonstrated human health benefits - BGH has no biological activity in humans due to low-affinity binding to human somatotropin receptors (animal studies)
• No oral bioavailability - completely degraded by digestive enzymes preventing any systemic effects (rat studies)
• Species-specific hormone - lacks cross-species activity making human supplementation ineffective (mechanistic studies)
• No clinical evidence - zero human clinical trials, RCTs, or meta-analyses exist evaluating BGH as a supplement
• Not approved for human use - developed exclusively for veterinary applications in dairy farming

How It Works

BGH exerts its effects in cattle by binding to bovine somatotropin receptors (bSTR), activating the JAK2-STAT5 intracellular signaling pathway to upregulate insulin-like growth factor 1 (IGF-1) synthesis in hepatic tissue, which drives mammary gland lactogenesis and somatic growth. In humans, structural divergence at receptor-binding domain residues means BGH binds human growth hormone receptors (hGHR) with approximately 1000-fold lower affinity than endogenous human GH, producing no measurable downstream STAT5 phosphorylation or IGF-1 elevation. Upon oral ingestion, gastric pepsin and pancreatic proteases hydrolyze BGH's peptide bonds within minutes, yielding inactive amino acid fragments incapable of systemic absorption as an intact hormone.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were identified evaluating BGH or rbST as a human supplement or therapeutic agent. Oral toxicity studies in rats (up to 1 mg/kg body weight/day) showed no biological activity or significant adverse effects. The research confirms BGH is species-specific and lacks activity in humans due to low-affinity binding to human somatotropin receptors.

Clinical Summary

No controlled human clinical trials have evaluated BGH supplementation for health outcomes, as the biological rationale for such trials is absent given established species-specificity and oral degradation. Animal pharmacokinetic studies in rats confirm that orally administered BGH produces no detectable rise in serum BGH or IGF-1, consistent with complete first-pass gastrointestinal proteolysis. Epidemiological reviews examining dairy consumption—which contains trace BGH residues—have not isolated any human health effect attributable specifically to BGH as distinct from other dairy constituents. Overall evidence quality is rated very low for any human bioactivity claim, and no regulatory body, including the FDA or EFSA, recognizes a human health benefit for BGH.

Nutritional Profile

BGH (Bovine Somatotropin/bST) is a 191-amino acid single-chain polypeptide hormone with a molecular weight of approximately 22,000 daltons. As a pure protein hormone, it contains no carbohydrates, lipids, vitamins, or minerals in its native form. Amino acid composition includes all 20 standard amino acids with notable concentrations of leucine (~20 residues), alanine (~18 residues), and glutamic acid (~17 residues). Contains 4 cysteine residues forming 2 disulfide bonds critical to tertiary structure. Caloric contribution is negligible at trace concentrations found in treated cow milk (~0.1 nanograms/mL above baseline). As a dietary protein source it is physiologically irrelevant — oral bioavailability is effectively 0% due to complete proteolytic degradation by pepsin, trypsin, and chymotrypsin in the gastrointestinal tract into constituent amino acids, which then enter the general amino acid pool indistinguishable from any other dietary protein. Residual levels in BGH-treated cow milk are estimated at 1–9 ng/mL total bST, representing a negligible protein contribution relative to milk's total protein content of approximately 30,000,000 ng/mL (3%). No bioactive intact hormone reaches systemic circulation following oral ingestion. Biologically active only via injection in cattle.

Preparation & Dosage

No clinically studied dosage ranges exist for human use in any form (extract, powder, or standardized), as BGH is not approved or studied as a human supplement and is completely degraded by digestive enzymes. BGH has no oral bioavailability and must be injected for veterinary efficacy. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Not applicable - BGH has no human supplement applications

Safety & Interactions

BGH consumed through dairy products or hypothetical oral supplementation poses no known toxicological risk in humans because it is fully degraded to amino acids prior to intestinal absorption, with no systemic exposure to intact hormone. No drug interactions have been identified, as BGH does not reach circulating concentrations in humans sufficient to engage any pharmacological target or compete with therapeutic agents at hGHR. BGH is not contraindicated in pregnancy or lactation based on oral exposure, though injected recombinant BGH (rbST) is a veterinary-only agent not intended for human administration and carries no established human safety profile for parenteral use. Individuals with milk protein allergies should note that BGH shares structural epitopes with bovine proteins, but it is not itself a documented allergen and is present in commercial dairy at negligible, highly variable concentrations.